ResMed (RMD) Scheduled to Post Quarterly Earnings on Thursday

ResMed (NYSE:RMD - Get Free Report) will be announcing its earnings results after the market closes on Thursday, April 25th. Analysts expect the company to announce earnings of $1.93 per share for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.

ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings data on Wednesday, January 24th. The medical equipment provider reported $1.88 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.81 by $0.07. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.15 billion. ResMed had a return on equity of 23.86% and a net margin of 19.77%. The firm's revenue was up 12.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.66 EPS. On average, analysts expect ResMed to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

ResMed Stock Performance

Shares of NYSE:RMD traded up $3.78 during mid-day trading on Thursday, reaching $177.61. 1,582,460 shares of the company traded hands, compared to its average volume of 1,005,330. The company's 50 day moving average price is $186.42 and its 200-day moving average price is $170.17. The firm has a market cap of $26.12 billion, a PE ratio of 28.74, a PEG ratio of 2.29 and a beta of 0.67. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.11 and a quick ratio of 1.89. ResMed has a 52 week low of $132.24 and a 52 week high of $243.52.

ResMed Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Thursday, February 8th were paid a dividend of $0.48 per share. The ex-dividend date of this dividend was Wednesday, February 7th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 1.08%. ResMed's dividend payout ratio (DPR) is presently 31.74%.

Insider Activity

In related news, Director Peter C. Farrell sold 10,935 shares of the firm's stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $182.66, for a total value of $1,997,387.10. Following the completion of the sale, the director now directly owns 157,404 shares in the company, valued at $28,751,414.64. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, General Counsel Michael J. Rider sold 200 shares of the firm's stock in a transaction on Friday, March 1st. The stock was sold at an average price of $173.25, for a total value of $34,650.00. Following the completion of the sale, the general counsel now directly owns 6,688 shares in the company, valued at $1,158,696. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Peter C. Farrell sold 10,935 shares of the firm's stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $182.66, for a total value of $1,997,387.10. Following the completion of the sale, the director now owns 157,404 shares of the company's stock, valued at $28,751,414.64. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,216 shares of company stock worth $2,046,617. 1.21% of the stock is currently owned by insiders.

Institutional Trading of ResMed

Institutional investors and hedge funds have recently made changes to their positions in the business. Compass Wealth Management LLC bought a new stake in shares of ResMed during the fourth quarter worth $26,000. Kayne Anderson Rudnick Investment Management LLC bought a new stake in shares of ResMed during the third quarter worth $26,000. Live Oak Investment Partners bought a new stake in shares of ResMed during the fourth quarter worth $44,000. Quarry LP bought a new stake in shares of ResMed during the second quarter worth $88,000. Finally, State of Wyoming bought a new stake in shares of ResMed during the second quarter worth $101,000. 54.98% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on RMD. Mizuho reiterated a "buy" rating and set a $215.00 price objective on shares of ResMed in a research note on Wednesday, March 27th. Oppenheimer increased their price objective on shares of ResMed from $185.00 to $205.00 and gave the company an "outperform" rating in a report on Tuesday, January 30th. UBS Group increased their price objective on shares of ResMed from $175.00 to $180.00 and gave the company a "neutral" rating in a report on Thursday, January 25th. Royal Bank of Canada increased their price objective on shares of ResMed from $181.00 to $182.00 and gave the company a "sector perform" rating in a report on Thursday, January 25th. Finally, Needham & Company LLC increased their price objective on shares of ResMed from $215.00 to $224.00 and gave the company a "buy" rating in a report on Monday, April 1st. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $199.20.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.